ClinicalTrials.gg
CompletedNCT00290901Updated Mar 3, 2021

Celebrex vs Tramadol in the Treatment of Chronic Lower Back Pain.

A Phase 4 interventional study of Tramadol Hydrochloride 50mg and Celebrex 200mg in Back Pain, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 54 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-03.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
754
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 307 studies in Back Pain with a site in United States — 38 open to participants now, 51 under way, 4 of them phase 3. Back Pain · United States.

Enrollment
11th of 262
754 · median 76
Started
2006
with 15 others
Phase 4
30 of 307
4 open now
Registered
19th of 307
by date

Among the 307 studies in Back Pain with a site in United States, this one is the 11th largest by enrollment of the 262 interventional ones that give a count, is one of 16 that started in 2006, is one of 30 in phase 4, and was the 19th registered.

Back Pain

728 studies on the registry are indexed under Back Pain; 109 are open to participants now.

Browse Back Pain studies →

Open to participants now

38 of the 307 studies in Back Pain with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Back Pain studies recruiting now, 29 (43%) set no upper age limit and 32 (47%) stop at 75 or younger; 3 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 307 studies in Back Pain with a site in United States, or all of them as a file.
02

Study summary

This study investigates if Celebrex is as effective as tramadol hydrochloride (Ultram) for patients with chronic low back pain, when administered over a 6-week period.

03

Conditions studied

  • Back Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject presents with duration of chronic low back pain of > 3 months requiring regular use of analgesics (> 4 days/week), except for acetaminophen which cannot have been the sole analgesic used.

Exclusion criteria

Exclusion Criteria:

  • The subject has chronic low back pain, which is neurologic in etiology (i.e., radiculopathy, neuropathy, myelopathy)
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
754 participants
06

What researchers measure

Primary outcomes

  1. To compare the analgesic effectiveness of celecoxib and tramadol in subjects with Chronic Low Back Pain measured by the Numerical Rating Scale (NRS-Pain) at Week 6.

Secondary outcomes

  1. To compare the effects of treatment with celecoxib 200 mg BID and tramadol hydrochloride 50 mg QID on improvement in functionality and quality of life in subjects with chronic low back pain.

07

Study locations

54 sites
  • Pfizer Investigational Site
    Phoenix, Arizona, United States
  • Pfizer Investigational Site
    Scottsdale, Arizona, United States
  • Pfizer Investigational Site
    Tucson, Arizona, United States
  • Pfizer Investigational Site
    Little Rock, Arkansas, United States
  • Pfizer Investigational Site
    Anaheim, California, United States
  • Pfizer Investigational Site
    La Mesa, California, United States
  • Pfizer Investigational Site
    Long Beach, California, United States
  • Pfizer Investigational Site
    Oceanside, California, United States
  • Pfizer Investigational Site
    Paramount, California, United States
  • Pfizer Investigational Site
    Sacramento, California, United States
  • Pfizer Investigational Site
    San Francisco, California, United States
  • Pfizer Investigational Site
    San Luis Obispo, California, United States
  • Pfizer Investigational Site
    Tustin, California, United States
  • Pfizer Investigational Site
    Vista, California, United States
  • Pfizer Investigational Site
    Boulder, Colorado, United States
  • Pfizer Investigational Site
    Colorado Springs, Colorado, United States
  • Pfizer Investigational Site
    Denver, Colorado, United States
  • Pfizer Investigational Site
    Cos Cob, Connecticut, United States
  • Pfizer Investigational Site
    Washington, District of Columbia, United States
  • Pfizer Investigational Site
    Miami, Florida, United States
  • Pfizer Investigational Site
    Pembroke Pines, Florida, United States
  • Pfizer Investigational Site
    West Palm Beach, Florida, United States
  • Pfizer Investigational Site
    Decatur, Georgia, United States
  • Pfizer Investigational Site
    Woodstock, Georgia, United States
  • Pfizer Investigational Site
    Libertyville, Illinois, United States
  • Pfizer Investigational Site
    Morton Grove, Illinois, United States
  • Pfizer Investigational Site
    Arkansas City, Kansas, United States
  • Pfizer Investigational Site
    Overland Park, Kansas, United States
  • Pfizer Investigational Site
    Wichita, Kansas, United States
  • Pfizer Investigational Site
    Madisonville, Kentucky, United States
  • Pfizer Investigational Site
    Baltimore, Maryland, United States
  • Pfizer Investigational Site
    Wheaton, Maryland, United States
  • Pfizer Investigational Site
    Jackson, Mississippi, United States
  • Pfizer Investigational Site
    Kansas City, Missouri, United States
  • Pfizer Investigational Site
    Saint Louis, Missouri, United States
  • Pfizer Investigational Site
    Omaha, Nebraska, United States
  • Pfizer Investigational Site
    Brooklyn, New York, United States
  • Pfizer Investigational Site
    New York, New York, United States
  • Pfizer Investigational Site
    Rochester, New York, United States
  • Pfizer Investigational Site
    Raleigh, North Carolina, United States
  • Pfizer Investigational Site
    Medford, Oregon, United States
  • Pfizer Investigational Site
    Portland, Oregon, United States
  • Pfizer Investigational Site
    Camp Hill, Pennsylvania, United States
  • Pfizer Investigational Site
    Duncansville, Pennsylvania, United States
  • Pfizer Investigational Site
    Charleston, South Carolina, United States
  • Pfizer Investigational Site
    Columbia, South Carolina, United States
  • Pfizer Investigational Site
    Johnson City, Tennessee, United States
  • Pfizer Investigational Site
    New Tazewell, Tennessee, United States
  • Pfizer Investigational Site
    Austin, Texas, United States
  • Pfizer Investigational Site
    San Angelo, Texas, United States
  • Pfizer Investigational Site
    San Antonio, Texas, United States
  • Pfizer Investigational Site
    Arlington, Virginia, United States
  • Pfizer Investigational Site
    Danville, Virginia, United States
  • Pfizer Investigational Site
    Rio Piedras, Puerto Rico
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2006 and a primary completion of Dec 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2006
First posted
Feb 13, 2006
Start
Mar 2006
Primary completionActual
Dec 2006
Last update
Mar 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00290901
Responsible party
Sponsor
First posted
Feb 13, 2006
Start date
Mar 2006
Primary completion
Dec 2006
Last update
Mar 3, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tramadol · Celecoxib

Start the discussion